Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients

Harrer DC, Heidenreich M, Fante MA, Mueller V, Haehnel V, Offner R, Burkhardt R, Herr W, Edinger M, Wolff D, Thomas S, Brosig A (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Transfusion Wiley

Book Volume: 62

Pages Range: 1602-1611

Journal Issue: 8

DOI: 10.1111/trf.17030

Abstract

Background: To date, in-depth analysis of leukapheresis products as starting material for CAR T-cell manufacturing, specifically Tisagenlecleucel production, are scarce. In this study, we report on lymphapheresis data for production of Tisagenlecleucel for elderly and pretreated lymphoma patients. Study Design and Methods: Spectra Optia from Terumo BCT, Lakewood, CO, was employed for apheresis using the cMNC program. Apheresis success was defined as meeting a target total nucleated cell (TNC) count of ≥2 × 109, a CD3-positive lymphocyte count of ≥1 × 109 and an overall viability of ≥70% in the lymphapheresis product. Results: Twenty-three patients (age 37–77 years) and 24 apheresis runs were evaluated. The median CD3-positive lymphocyte count in peripheral blood at the beginning of apheresis was 565 cells/μl (range: 70–1345 cells/μl). Circulating lymphoma cells were detected in one patient prior to apheresis. Target criteria were met in 21 of 23 patients. The median TNC count in the apheresate was 11.2 × 109 (range: 2.9 × 109–47.4 × 109). The median CD3-positive lymphocyte count in the apheresate was 2.55 × 109 (range: 0.370 × 109–6.915 × 109), which resulted in a median collection efficiency for CD3-positive lymphocytes of 63.7% (range: 9.56%–93.6%). No adverse events associated with the apheresis process were observed. Conclusions: Lymphapheresis with the Spectra Optia cMNC program provided a sufficient quantity of CD3-positive lymphocytes for CAR T-cell manufacturing for the majority of patients despite their heavy pretreatment and advanced age. Moreover, we are the first to advocate early pre-emptive lymphocyte collection in DLBCL-NOS patients intended to undergo treatment with Tisagenlecleucel.

Involved external institutions

Universitätsklinikum Regensburg DE Germany (DE)

How to cite

APA:

Harrer, D.C., Heidenreich, M., Fante, M.A., Mueller, V., Haehnel, V., Offner, R.,... Brosig, A. (2022). Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients. Transfusion, 62(8), 1602-1611. https://doi.org/10.1111/trf.17030

MLA:

Harrer, Dennis Christoph, et al. "Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients." Transfusion 62.8 (2022): 1602-1611.

BibTeX: Download